

Alessandra Lugaresi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8570938/alessandra-lugaresi-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

239
papers

8,146
citations

50
h-index

77
g-index

252
ext. papers

9,572
ext. citations

5.4
avg, IF

5.15
L-index

#	Paper	IF	Citations
239	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	4
238	Comparing natural history of early and late onset pediatric multiple sclerosis.. <i>Annals of Neurology</i> , 2022 ,	9.4	2
237	Cannabis-Based Products in a Neurological Setting: A Clinical and Pharmacokinetic Survey.. <i>Frontiers in Neurology</i> , 2022 , 13, 784748	4.1	0
236	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221084577	5	0
235	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021 , 96, e783-e797	6.5	18
234	Inflammatory optic neuropathy following SARS-CoV-2 mRNA vaccine: Description of two cases. <i>Journal of the Neurological Sciences</i> , 2021 , 429, 118186	3.2	2
233	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. <i>Neurology</i> , 2021 , 96, e214-e227	6.5	2
232	Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review. <i>Frontiers in Neurology</i> , 2021 , 12, 554375	4.1	4
231	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , 2021 ,	6	6
230	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
229	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211023365	5	2
228	A Pilot Study of 24-h Motor Activity Patterns in Multiple Sclerosis: Pre-Planned Follow-Up at 2 Years. <i>Clocks & Sleep</i> , 2021 , 3, 366-376	2.9	
227	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021 , 78, 726-735	17.2	4
226	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 755-766	5	3
225	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 695-705	5	4
224	Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31. <i>Neurological Sciences</i> , 2021 , 42, 1395-1403	3.5	4
223	Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. <i>European Journal of Neurology</i> , 2021 , 28, 567-578	6	4

222	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 430-438	5	1
221	Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2021 , 28, 269-277	6	
220	Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. <i>Neuroepidemiology</i> , 2021 , 55, 224-231	5.4	0
219	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1838-1851	5	2
218	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103012	4	3
217	Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial. <i>BMJ Open</i> , 2021 , 11, e052012	3	0
216	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021 , 35, 1217-1232	6.7	1
215	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. <i>Health and Quality of Life Outcomes</i> , 2021 , 19, 224	3	
214	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021 , 430, 118067	3.2	0
213	The impact of the COVID-19 pandemic on people with neurological disorders: an urgent need to enhance the health care system preparedness. <i>Neurological Sciences</i> , 2021 , 42, 799-804	3.5	5
212	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.. <i>Pharmacoeconomics</i> , 2021 , 40, 323	4.4	
211	The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study.. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211064121	5	1
210	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020 , 143, 1400-1413	11.2	13
209	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , 2020 , 19, 307-316	24.1	77
208	Listening to the neurological teams for multiple sclerosis: the SMART project. <i>Neurological Sciences</i> , 2020 , 41, 2231-2240	3.5	5
207	Assessing measurement invariance of MSQOL-54 across Italian and English versions. <i>Quality of Life Research</i> , 2020 , 29, 783-791	3.7	2
206	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1765-1774	5	5
205	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101868	4	15

204	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 1297-1303	5.5	13
203	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , 2020 , 417, 117064	3.2	0
202	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020 , 77, 1398-1407	17.2	8
201	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756	11.2	8
200	Ponesimod for the treatment of relapsing multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1955-1964	4	6
199	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 79-90	5	27
198	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019 , 10, 916	4.1	10
197	Sleep-related disorders and their relationship with MRI findings in multiple sclerosis. <i>Sleep Medicine</i> , 2019 , 56, 90-97	4.6	25
196	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 856-866	5	5
195	Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1309-1320	4	2
194	Circadian Activity Rhythm in Early Relapsing-Remitting Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
193	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019 , 40, 155-165	3.5	42
192	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 458-468	5.5	46
191	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 235-243	4	22
190	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187	27.4	172
189	Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 261-267	5.5	15
188	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019 , 26, 363-370	6	8
187	Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis. <i>Neurological Sciences</i> , 2019 , 40, 75-80	3.5	8

186	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 166	4	
185	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 19, 105-108	4	15
184	Arthritic psoriasis during natalizumab treatment: a case report and review of the literature. <i>Neurological Sciences</i> , 2018 , 39, 181-183	3.5	4
183	First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1803-1807	2.5	11
182	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 642-652	5	18
181	Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 663-674	5	24
180	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1617-1626	5	21
179	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018 , 75, 1407-1415	17.2	13
178	Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. <i>PLoS ONE</i> , 2018 , 13, e0200532	3.7	8
177	Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship. <i>Clinical Neuropharmacology</i> , 2018 , 41, 171-176	1.4	4
176	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018 , 265, 2851-2860	5.5	24
175	Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1569-1577	5	3
174	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 24, 11-19	4	12
173	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018 , 391, 72-76	3.2	11
172	Teeth loss after teriflunomide treatment: Casual or causal? A short case series. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 24, 120-122	4	3
171	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 266-276	5	22
170	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 196-203	5.5	43
169	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , 2017 , 16, 271-281	24.1	101

168	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017 , 81, 729-739	9.4	26
167	Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?. <i>Journal of the Neurological Sciences</i> , 2017 , 378, 233-237	3.2	9
166	"Nail loss after teriflunomide treatment: A new potential adverse event". <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 170-172	4	4
165	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017 , 89, 1050-1059	6.5	31
164	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017 , 2,	0	3
163	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. <i>Neurological Sciences</i> , 2017 , 38, 53-59	3.5	22
162	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1346-1357	5	13
161	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017 , 140, 2426-2443	11.2	62
160	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. <i>Frontiers in Psychology</i> , 2017 , 8, 2216	3.4	19
159	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. <i>Journal of Clinical Psychology in Medical Settings</i> , 2016 , 23, 33-52	2	27
158	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 520-32	5	30
157	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1133-7	5.5	57
156	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016 , 80, 89-100	9.4	117
155	Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016 , 366, 139-145	3.2	17
154	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. <i>Neurological Sciences</i> , 2016 , 37, 613-22	3.5	9
153	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. <i>PLoS ONE</i> , 2016 , 11, e0153466	3.7	20
152	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. <i>PLoS ONE</i> , 2016 , 11, e0157721	3.7	3
151	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016 , 139, 2395-405	11.2	172

150	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , 2016 , 23, 729-36	6	19
149	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1343-1349	5.5	44
148	Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β 1a using an electronic device: the RIVER study. <i>Expert Opinion on Drug Delivery</i> , 2016 , 13, 931-5	8	12
147	Comparative efficacy of first-line natalizumab vs IFN- β 1r glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016 , 6, 102-115	1.7	21
146	Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. <i>Quality of Life Research</i> , 2016 , 25, 2755-2763	3.7	7
145	Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure. <i>Health Expectations</i> , 2016 , 19, 437-47	3.7	9
144	An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis. <i>Molecular BioSystems</i> , 2015 , 11, 1563-72		57
143	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 479-91	5.3	36
142	Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 295-306	5.5	7
141	BREMSO: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015 , 22, 981-9	6	23
140	Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. <i>JAMA Neurology</i> , 2015 , 72, 405-13	17.2	83
139	How many injections did you miss last month? A simple question to predict interferon β 1a adherence in multiple sclerosis. <i>Expert Opinion on Drug Delivery</i> , 2015 , 12, 1829-35	8	22
138	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3275-86	11.2	63
137	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3287-98	11.2	107
136	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1159-71	5	30
135	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 373-87	5.3	42
134	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015 , 15, 204	3.1	28
133	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015 , 1, 2055217315600193		

132	Patient expression of emotions and neurologist responses in first multiple sclerosis consultations. <i>PLoS ONE</i> , 2015 , 10, e0127734	3.7	19
131	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 184	2.8	24
130	Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. <i>Neurology</i> , 2015 , 84, 981-8	6.5	155
129	Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. <i>Journal of Neuroinflammation</i> , 2015 , 12, 146	10.1	19
128	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015 , 77, 425-35	9.4	118
127	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015 , 10, e0122686	3.7	80
126	Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014 , 35, 307-16	3.5	28
125	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 739-46	5	104
124	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014 , 82, 1204-11	6.5	113
123	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014 , 76, 880-90	9.4	57
122	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. <i>Journal of the Neurological Sciences</i> , 2014 , 337, 67-73	3.2	28
121	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014 , 14, 114	3.1	22
120	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014 , 14, 65	3.1	43
119	Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. <i>PLoS ONE</i> , 2014 , 9, e109679	3.7	53
118	Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2014 , 14, 1029-42	4.3	42
117	Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. <i>International Journal of Immunopathology and Pharmacology</i> , 2014 , 27, 147-54	3	17
116	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 845-50	5.5	48
115	The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014 , 14, 171	3.1	78

114	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1511-22	5	49
113	Implementation of the Sapere MiglioraQnformation aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1234-43	5	12
112	Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial. <i>Health Expectations</i> , 2014 , 17, 36-48	3.7	11
111	Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. <i>Journal of Neurology</i> , 2013 , 260, 1583-93	5.5	25
110	Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. <i>Journal of Neurology</i> , 2013 , 260, 1258-62	5.5	7
109	RebiSmart (version 1.5) device for multiple sclerosis treatment delivery and adherence. <i>Expert Opinion on Drug Delivery</i> , 2013 , 10, 273-83	8	26
108	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013 , 136, 3609-17	11.2	96
107	Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e63480	3.7	22
106	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013 , 34, 1633-7	3.5	17
105	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1508-17	5	35
104	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1106-12	5	50
103	Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis. <i>Proteomics</i> , 2013 , 13, 1002-9	4.8	16
102	Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 893-914	3.1	26
101	Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments. <i>PLoS ONE</i> , 2013 , 8, e60721	3.7	32
100	Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study. <i>International Journal of Clinical Practice</i> , 2012 , 66, 504-14	2.9	15
99	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012 , 12, 124	3.1	72
98	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012 , 12, 165	3.1	66
97	Patient adherence to and tolerability of self-administered interferon β 1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. <i>BMC Neurology</i> , 2012 , 12, 7	3.1	42

96	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012 , 318, 94-9	3.2	27
95	Improving patient-physician dialog: commentary on the results of the MS Choices survey. <i>Patient Preference and Adherence</i> , 2012 , 6, 143-52	2.4	17
94	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 835-42	5	95
93	Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 12656-64	6.3	44
92	The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 305-10	5.5	27
91	Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. <i>PLoS ONE</i> , 2012 , 7, e38661	3.7	29
90	Supportive strategies to improve adherence to IFN β 1b in multiple sclerosis--results of the Plus observational cohort study. <i>Journal of the Neurological Sciences</i> , 2011 , 307, 120-6	3.2	54
89	Anxiety and depression in multiple sclerosis patients around diagnosis. <i>Journal of the Neurological Sciences</i> , 2011 , 307, 86-91	3.2	85
88	Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. <i>Journal of Proteomics</i> , 2011 , 74, 2826-36	3.9	59
87	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. <i>Neurological Sciences</i> , 2011 , 32, 351-8	3.5	15
86	The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. <i>Neurological Sciences</i> , 2011 , 32, 1035-41	3.5	20
85	Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. <i>Journal of Translational Medicine</i> , 2011 , 9, 42	8.5	9
84	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1355-9	5.5	17
83	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011 , 77, 1887-95	6.5	59
82	Breastfeeding is not related to postpartum relapses in multiple sclerosis. <i>Neurology</i> , 2011 , 77, 145-50	6.5	116
81	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 100-11	5	38
80	An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1393-405	5	58
79	Pregnancy and fetal outcomes after interferon- β exposure in multiple sclerosis. <i>Neurology</i> , 2010 , 75, 1794-802	6.5	121

78	Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1237-47	5	22
77	Protein profiling of Guillain-Barré syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry. <i>Neuroscience Letters</i> , 2010 , 485, 49-54	3.3	23
76	Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. <i>BMC Neurology</i> , 2010 , 10, 28	3.1	44
75	Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. <i>Journal of Proteomics</i> , 2010 , 73, 579-92	3.9	37
74	A computational platform for MALDI-TOF mass spectrometry data: application to serum and plasma samples. <i>Journal of Proteomics</i> , 2010 , 73, 562-70	3.9	28
73	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 779-88	5	141
72	Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009 , 66, 513-20	9.4	109
71	Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?. <i>Expert Opinion on Drug Delivery</i> , 2009 , 6, 995-1002	8	61
70	Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009 , 286, 109-13	3.2	22
69	Independent component analysis for the extraction of reliable protein signal profiles from MALDI-TOF mass spectra. <i>Bioinformatics</i> , 2008 , 24, 63-70	7.2	57
68	Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone). <i>Multiple Sclerosis Journal</i> , 2008 , 14, 739-48	5	25
67	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1225-33	5	58
66	Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. <i>Clinical Neuropharmacology</i> , 2008 , 31, 167-72	1.4	23
65	Cleavage of cystatin C is not associated with multiple sclerosis. <i>Annals of Neurology</i> , 2007 , 62, 201-4; discussion 205	9.4	33
64	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 1068-70	5	45
63	Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 814-23	5	173
62	Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 77-87	5	98
61	Mononeuropathy following subcutaneous interferon-beta injection. <i>Journal of Neurology</i> , 2006 , 253, 961-2	5.5	1

60	Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. <i>Journal of the Neurological Sciences</i> , 2005 , 237, 5-11	3.2	13
59	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. <i>Neurological Sciences</i> , 2005 , 26 Suppl 4, S200-3	3.5	15
58	Demyelinating motor Guillain-Barré syndrome following rubella. <i>Neurology</i> , 2005 , 64, 390	6.5	4
57	Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. <i>Journal of Neuroimmunology</i> , 2004 , 150, 123-31	3.5	39
56	IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors. <i>Experimental Gerontology</i> , 2004 , 39, 653-7	4.5	26
55	Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251, 1208-14	5.5	114
54	The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy. <i>Annals of Neurology</i> , 2004 , 56, 631-41	9.4	88
53	Acute motor conduction block neuropathy Another Guillain-Barré syndrome variant. <i>Neurology</i> , 2003 , 61, 617-22	6.5	108
52	Apolipoprotein E genotype does not influence the progression of multiple sclerosis. <i>Journal of Neurology</i> , 2003 , 250, 1094-8	5.5	35
51	Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002 , 123, 170-9	3.5	23
50	The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. <i>Journal of Neurology</i> , 2002 , 249, 152-63	5.5	74
49	Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?. <i>Clinical Neurophysiology</i> , 2002 , 113, 346-53	4.3	56
48	Lymphomononuclear cells from multiple sclerosis patients spontaneously produce high levels of oncostatin M, tumor necrosis factors alpha and beta, and interferon gamma. <i>Multiple Sclerosis Journal</i> , 2002 , 8, 284-8	5	22
47	Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. <i>Neurology</i> , 2001 , 57, 62-8	6.5	139
46	Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. <i>Neurological Sciences</i> , 2001 , 22, 209-10	3.5	21
45	Anti-GD1a antibodies from an acute motor axonal neuropathy patient selectively bind to motor nerve fiber nodes of Ranvier. <i>Journal of Neuroimmunology</i> , 2001 , 121, 79-82	3.5	28
44	RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. <i>Journal of Neuroimmunology</i> , 2000 , 107, 100-7	3.5	54
43	Effect of rhTNF-alpha injection into rat sciatic nerve. <i>Journal of Neuroimmunology</i> , 1999 , 94, 88-94	3.5	26

42	Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neuroimmunology</i> , 1999 , 95, 190-4	3.5	29
41	Steroid-responsive multifocal demyelinating neuropathy with central involvement. <i>Muscle and Nerve</i> , 1999 , 22, 262-5	3.4	10
40	Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor nerve terminal block. <i>Muscle and Nerve</i> , 1999 , 22, 640-4	3.4	40
39	Chronic inflammatory demyelinating polyneuropathy in diabetics: motor conductions are important in the differential diagnosis with diabetic polyneuropathy. <i>Clinical Neurophysiology</i> , 1999 , 110, 705-11	4.3	58
38	Minimal and asymptomatic chronic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 1999 , 110, 694-8	4.3	33
37	Interferon beta normalizes suppressor cell function in dysimmune neuropathies. <i>Journal of Neuroimmunology</i> , 1998 , 82, 1-4	3.5	15
36	Acute motor axonal neuropathy with high titer IgG and IgA anti-GD1a antibodies following <i>Campylobacter</i> enteritis. <i>Journal of the Neurological Sciences</i> , 1997 , 147, 193-200	3.2	38
35	Distal myasthenia gravis and sensory neuronopathy with anti-50 kDa antibody mimicking sensory-motor neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 63, 414-5	5.5	6
34	Chronic progressive steroid responsive axonal polyneuropathy: a CIDP variant or a primary axonal disorder?. <i>Muscle and Nerve</i> , 1996 , 19, 365-71	3.4	29
33	Trigemino-facial reflex in lingual neuropathy. <i>Muscle and Nerve</i> , 1996 , 19, 1636-7	3.4	2
32	Abnormal brain and muscle energy metabolism shown by ³¹ P-MRS in familial hemiplegic migraine. <i>Journal of the Neurological Sciences</i> , 1995 , 129, 214-22	3.2	60
31	Hand dystonia secondary to cervical demyelinating lesion. <i>Acta Neurologica Scandinavica</i> , 1994 , 90, 51-5	3.8	23
30	Benign monomelic amyotrophy of lower limb: a rare entity with a characteristic muscular CT. <i>Journal of the Neurological Sciences</i> , 1994 , 126, 153-61	3.2	26
29	Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. <i>Muscle and Nerve</i> , 1993 , 16, 610-5	3.4	97
28	Basal ganglia involvement in multiple sclerosis with alternating side paroxysmal dystonia. <i>Journal of Neurology</i> , 1993 , 240, 257-8	5.5	12
27	Sympathetic skin response in hemispheric lesions. <i>Neurophysiologie Clinique</i> , 1992 , 22, 475-81	2.7	11
26	Anti-sulfatide antibodies in neurological disease: binding to rat dorsal root ganglia neurons. <i>Journal of the Neurological Sciences</i> , 1992 , 112, 152-9	3.2	51
25	Isolated bovine spinal motoneurons have specific ganglioside antigens recognized by sera from patients with motor neuron disease and motor neuropathy. <i>Journal of Neurochemistry</i> , 1992 , 59, 1684-91		15

24	Isolated failure of noradrenergic transmission in a case with orthostatic hypotension and hyperactivity of gastro-colic reflex. <i>Clinical Autonomic Research</i> , 1992 , 2, 177-82	4.3	3
23	Autonomic nervous system function in myotonic dystrophy. <i>Italian Journal of Neurological Sciences</i> , 1992 , 13, 589-92		8
22	Idiopathic recurring stupor: a case with possible involvement of the gamma-aminobutyric acid (GABA)ergic system. <i>Annals of Neurology</i> , 1992 , 31, 503-6	9.4	39
21	Patterns of reactivity of human anti-GM1 antibodies with spinal cord and motor neurons. <i>Annals of Neurology</i> , 1992 , 32, 487-93	9.4	65
20	HTLV-1-associated myeloneuropathy in an Italian. <i>Acta Neurologica Scandinavica</i> , 1991 , 84, 186-91	3.8	5
19	Sleep apneas, convulsive syncopes and autonomic impairment in type I Arnold-Chiari malformation. <i>European Neurology</i> , 1991 , 31, 36-40	2.1	22
18	Identification of glycoconjugates which are targets for anti-Gal(beta 1-3)GalNAc autoantibodies in spinal motor neurons. <i>Journal of Neuroimmunology</i> , 1991 , 34, 69-76	3.5	21
17	Amplifications of multiple regions of the HTLV-I genome from DNA of an Italian spastic paraparesis patient but not from DNA of multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 1991 , 103, 82-9	3.2	5
16	Psychic akinesia following carbon monoxide poisoning. <i>European Neurology</i> , 1990 , 30, 167-9	2.1	25
15	Severe dysautonomic onset of Guillain-Barré syndrome with good recovery. A clinical and autonomic follow-up study. <i>Italian Journal of Neurological Sciences</i> , 1990 , 11, 159-62		13
14	Recurrent cranial nerve palsies, midbrain infarction and hydrocephalus due to megadolichobasilar artery. <i>Italian Journal of Neurological Sciences</i> , 1990 , 11, 489-92		2
13	Diurnal variability in cranial dystonia. <i>Movement Disorders</i> , 1990 , 5, 44-6	7	10
12	F response in vascular and degenerative upper motor neuron lesions. <i>Neurophysiologie Clinique</i> , 1990 , 20, 259-68	2.7	3
11	Transdermal scopolamine cycloplegia in juvenile diabetes. <i>Italian Journal of Neurological Sciences</i> , 1989 , 10, 203-5		1
10	Physiological hypnic myoclonus. <i>Electroencephalography and Clinical Neurophysiology</i> , 1988 , 70, 172-6		43
9	Extrapyramidal syndrome and depression induced by flunarizine. <i>European Neurology</i> , 1988 , 28, 208-11	2.1	27
8	Fatal familial insomnia and dysautonomia. <i>New England Journal of Medicine</i> , 1987 , 316, 1027-8	59.2	1
7	Lack of vegetative and endocrine circadian rhythms in fatal familial thalamic degeneration. <i>Clinical Endocrinology</i> , 1987 , 26, 573-80	3.4	25

6	Fasciculations during wakefulness and sleep. <i>Acta Neurologica Scandinavica</i> , 1987 , 76, 152-4	3.8	12
5	Autonomic failure in a case of Chiari malformation type I. <i>Functional Neurology</i> , 1987 , 2, 511-3	2.2	1
4	Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. <i>New England Journal of Medicine</i> , 1986 , 315, 997-1003	59.2	582
3	Effect of oxygen radicals and hyperoxia on rat heart ornithine decarboxylase activity. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1982 , 718, 157-64	4	24
2	Early clinical markers of aggressive multiple sclerosis		1
1	Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years		1